Literature DB >> 2450679

Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

J M McCune1, L B Rabin, M B Feinberg, M Lieberman, J C Kosek, G R Reyes, I L Weissman.   

Abstract

The envelope protein of human immunodeficiency virus (HIV) is synthesized as a polyprotein (gp160) and cleaved intracellularly to a gp120-gp41 heterodimer. In this study, the tryptic-like endoproteolytic cleavage site was removed by site-directed mutagenesis and replaced with a chymotryptic-like site. The resultant mutant, RIP7/mut10, was found to be indistinguishable from wild-type HIV when analyzed at the level of proviral replication, RNA processing, protein expression, and viral assembly. However, the gp160 polyprotein was not cleaved and the mutated virions were biologically inactive, until and unless they were exposed to limiting concentrations of chymotrypsin. As is the case for other enveloped mammalian viruses, endoproteolytic cleavage of the HIV envelope protein and release of a unique hydrophobic domain appear to be necessary for the full expression of viral infectivity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450679     DOI: 10.1016/0092-8674(88)90487-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  259 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein sigma3.

Authors:  Judit Jané-Valbuena; Laura A Breun; Leslie A Schiff; Max L Nibert
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Viral DNA carried by human immunodeficiency virus type 1 virions.

Authors:  F Lori; F di Marzo Veronese; A L de Vico; P Lusso; M S Reitz; R C Gallo
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 5.  Membrane fusion of enveloped viruses: especially a matter of proteins.

Authors:  D Hoekstra
Journal:  J Bioenerg Biomembr       Date:  1990-04       Impact factor: 2.945

6.  Biosynthesis, maturation, and acid activation of the Semliki Forest virus fusion protein.

Authors:  M Kielian; S Jungerwirth; K U Sayad; S DeCandido
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  HIV-1 Envelope Glycoprotein Trafficking through the Endosomal Recycling Compartment Is Required for Particle Incorporation.

Authors:  Junghwa Kirschman; Mingli Qi; Lingmei Ding; Jason Hammonds; Krista Dienger-Stambaugh; Jaang-Jiun Wang; Lynne A Lapierre; James R Goldenring; Paul Spearman
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

8.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.

Authors:  T D Duensing; H Fang; D W Dorward; S H Pincus
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1.

Authors:  Y Ohnishi; T Shioda; K Nakayama; S Iwata; B Gotoh; M Hamaguchi; Y Nagai
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.